EMA Approves Aptar Pharma’s Electronic Lockout Device
Aptar Pharma has received the approval by the European Medicines Agency for the integrated electronic nasal lockout device (e-Lockout) following a multi-year development with Takeda Pharmaceuticals International.
Instanyl is a fast-acting nasal opioid approved for relieving breakthrough pain in adult cancer patients already treated with opioids. The system’s built-in lock-out mechanism prevents the device from being used for a period of time after a pre-defined number of spray actuations. The electronic display shows the number of priming strokes, the number of doses left in the device and whether the nasal spray is locked or ready for use.
The EMA has granted marketing authorization for this multidose nasal spray treatment under the name, Instanyl DoseGuard. — Cynthia Jessup